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The search for new, robust, and reproducible biomarkers for Alzheimer’s disease (AD)
diagnosis is a challenge.Werecently reported that salivary lactoferrin (Lf) couldbepre-
sented as newbiomarker candidate for AD, being both non-invasive and cost-effective,
as well as having appropriate diagnostic performance for the clinical detection of AD
subjects. Saliva is an attractive sample type for biomarker-based testing approaches
for several other diseases; however, its compositionmay change under certain circum-
stances. It is therefore critical to maintain a consistent salivary handling protocol, con-
sidering possible extrinsic factors that may influence salivary Lf concentration. In this
work, we analyzed salivary Lf concentration under different handling conditions and
donor-dependent factors including age, inter-diurnal variations, physical activity, and
pharmacological treatments. Our aim was to evaluate the influence of such conditions
on salivary Lf concentration. In conclusion, we found that most of these extrinsic fac-
tors should be considered in the futurewhen using Lf as a predictive biomarker for AD.
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1 NARRATIVE
In searching for possible robust biomarkers for Alzheimer’s disease
(AD), researchers worldwide unanimously agreed to establish consis-
tent criteria. These criteria include samples that are easy to collect,
of high sensitivity and specificity, inexpensive in commercial test for-
mat, with clear cut-off values, and having reproducible results over
time. We recently reported the potential of salivary lactoferrin (Lf) as
a candidate biomarker for AD as it meets the above-mentioned crite-
ria. By examining two independent cohorts, our results showed that
reduced salivary Lf levels are specific for AD. This potential biomarker
displayed accurate parameters with very high sensitivity and speci-
ficity, combined with being non-invasive and cost-effective features
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for a good biomarker.1 Salivary biomarkers are promising candidates
for the diagnosis and monitoring of neurological diseases.2–4 It has
been shown that Lf is useful in the diagnosis and management of other
diseases, including periodontitis, inflammation, and gastrointestinal
diseases,5–6 as well as in salivary gland carcinoma.7 Although saliva is
the source of an attractive field for biomarker-based testing for sev-
eral diseases, it is important to consider factors thatmay influence sali-
vary Lf concentration.8 This is because saliva composition may change
under certain circumstances, including sampling processing, and many
environmental and lifestyle factors.9 To confirm the hypothesis that
salivary Lf is suitable as a diagnostic biomarker for AD, key aspects that
must be taken into account are debated here before the use of this
biomarker in future clinical practice. One key point is the storage and
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maintenance of salivary samples to avoid changes in protein concen-
tration between the collection time and the time when the analysis is
carried out.
Saliva flow ratemay vary depending upon collection time during the
day,10 therefore research should be carried out minimizing the possi-
ble circadian variability on salivary Lf production. Another key aspect
thatwemust consider is donor age as itmay influence salivary Lf levels.
Among the elderly population, susceptibility to infections is increased
and themain reason could be a reduced adaptive immunity response.11
Because salivary Lf is an important innate-immune defense element,
we sought to determinewhether healthy aging correlates with optimal
salivary Lf production.
Physical activity may also influence Lf levels. Epidemiologic data
suggest that regular physical activity may slow the rate of cognitive
decline and thus delay or prevent dementia.12–13 Acute exercise with
moderate intensity has been shown to increase antimicrobial protein
concentration in saliva and particularly Lf levels (when levels are com-
pared before and immediately after exercise).14 Noticeably, 1 hour
after finishing exercise, salivary Lf levels returned to the initial values
registered before exercise.14
Theutility of salivary Lf as adiagnostic biomarker forADwill depend
upon the impact on its concentration of currently used treatments.
In particular, the National Institute for Health and Care Excellence
(NICE) recommends the use of acetylcholinesterase (AChE) inhibitors
for patients with mild-to-moderate AD and memantine for severe AD.
AChEmediates acetylcholine catabolismand salivary protein secretion
may be mediated by acetylcholine release under autonomic nervous
system control.15 Hence, AChE inhibitors may influence the Lf levels
by increasing acetylcholine levels.
The present work aimed to study the effects of different pre-
analytical handling procedures (including storage at different tempera-
tures and the freezing/thawing cycles) and regulatory extrinsic factors
(including aging, circadian rhythm, exercise, and AD medications) that
may influence salivary Lf production in donors.We found that extrinsic
factors such as temperature and consecutive freezing/thawing cycles
affect Lf concentration in salivary samples. However, it is important to
note that 4◦C sample maintenance of up to 10 days while maintaining
less than three freezing/thawing cycles does not significantly modify
Lf concentration. This condition facilitates sample transport and anal-
ysis making the process easier and more cost-effective. Therefore, we
recommend a standardized collection and storage protocol to replicate
studies and to ensure that the statistical power is not compromised by
preanalytical factors.We recommend freezing saliva samples after col-
lection at –80◦C into aliquots to ensure the long-term stability of Lf.
Small aliquot volumes are optimal to avoid freezing/thawing cycles by
requiring only one aliquot to be thawed andmaintained at 4◦C for sub-
sequent analysis of Lf levels.
For biomarkers that are influenced by circadian rhythms, the collec-
tion time is important. However, we did not find any significant diurnal
variation impact on salivary Lf levels. As it often is difficult to accom-
plish standardization of sample acquisition time in daily clinical prac-
tice, a more rigorous study collecting samples for evaluation every
8hoursduring aday shouldbeperformed.Meanwhile, to avoidpossible
RESEARCH INCONTEXT
1. Systematic review: The association between “salivary
lactoferrin (Lf)” and “Alzheimer’s disease (AD) biomark-
ers” and the terms: “pre-analytical handling procedures”
(including temperature storage and freezing/thawing
cycles), “regulatory extrinsic factors” (including aging,
circadian rhythm, exercise, and AD medications) and
“standardized protocols,” was reviewed in the literature.
Lately, there have been intensified efforts in searching
for minimally or non-invasive peripheral markers for the
early diagnosis of AD, focused on blood and/or saliva.
We have recently showed that salivary Lf discriminates
between patients with mild cognitive impairment (MCI)
and AD and control subjects.
2. Interpretation: We found that handling conditions and
donor-dependent factors including age, between-day
variations, physical activity, and medication, may influ-
ence salivary Lf concentration. These results support the
recommendation to maintain a consistent salivary han-
dling protocol, considering possible extrinsic factors that
may impact salivary Lf concentration. All these extrinsic
factors must be considered for future validation of sali-
vary Lf as an AD biomarker.
3. Future direction: These recommendations provide
a checklist for standardizing collection protocols to
establish large cohorts of well-characterized samples in
biomarker research studies. Future works should use
the suggested standardized procedures as prerequisite
ensuring data replication, and guaranteeing that Lf levels
are not compromised by pre-analytical factors.
modifications of salivary Lf levels in collected samples, we recommend
carrying out the collection at the same time of the daywith every single
donor.
Extrinsic factors such as age, moderate physical activity, and medi-
cal treatments may modify salivary Lf production in donors. Although
salivary Lf levels may vary with age, these variations do not occur in
subjects within the same range of age. Therefore, to compare Lf levels
between healthy and AD subjects we recommend collecting samples
within age-matched grouped donors for comparison. Information on
the age at sampling is necessary to allow comparisons with the age ref-
erence value. As salivary Lf levels undergo an acute increase after exer-
cise and these high levels remain for at least for 1 hour, we, recommend
collection of samples during rest or at least 1 hour after completion of
any intense or moderate physical activity, to avoid false increases in Lf
levels. Medication can influence the reference range of biomarkers, so
this clinical informationmust be providedwith each sample. Treatment
withAChE inhibitorsmay affect salivary Lf levels increasing its concen-
tration and this could be a consequence of treatment itself. To confirm
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that AChE inhibitor treatment increases salivary Lf levels, we recom-
mend carrying out future longitudinal studies analyzing salivary Lf lev-
els in treated or untreated patients separately, facilitating disease pro-
gressionmonitoring.
In conclusion, all these extrinsic factors must be considered for
future validation of salivary Lf as anADbiomarker. In summary, we rec-
ommend the above-proposed procedures for handling and maintain-
ing samples for all research groups or labs focused on the validation
of salivary Lf levels as a biomarker for AD. Additionally, we encourage
consideration of variations in salivary Lf levels that might be related
to age, lifestyle, and ongoing patient treatments. These recommenda-
tions provide a checklist for standardizing collection to establish large
cohorts of well-characterized samples in biomarker research studies.
The suggested standardized protocols are a prerequisite to ensuring
data reproducibility, similarly they also guarantee that the statistical
power gained by increasing the numbers of saliva samples is not com-
promised by pre-analytical factors.
2 CONSOLIDATED RESULTS AND STUDY
DESIGN
We have analyzed Lf concentration in salivary samples under different
storage conditions by enzyme-linked immunosorbent assays (ELISAs).
Then, we evaluated possible variations in Lf concentration in saliva
samples from donors (healthy subjects and AD patients) in different
experimental conditions, varying circadian rhythm, age, exercise, and
AD medication (AChE inhibitors, and memantine). Additionally, total
protein content in saliva samples was evaluated according to whether
the patients were under treatment or not. In all cases, salivary Lf con-
centration was measured using the Lf human ELISA kit (ab200015,
Abcam) and total protein content was estimated by the bicinchoninic
acid (BCA) method (Pierce). For all measurements, except for the anal-
ysis of Lf concentration after several freezing/thawing cycles, saliva
samples underwent one freezing/thawing cycle only. Finally, statisti-
cal analysis for multiple comparisons was calculated by one-way anal-
ysis of variance followed by Fisher’s least significant difference correc-
tion. Student’s t-testwas used for single pairwise comparisons. Statisti-
cal analysis and exponential curve fittingwere performed usingGraph-
Pad Prism6.01 (GraphPad Software). Datawere generated from amin-
imum of three independent measurements by triplicate. All data are
expressed as mean ± standard error of the mean (SEM) or ± standard
deviation (SD) when appropriate. Grubbs outlier filter was used for all
data. In all cases, statistical significance was set at P < .05 (*P < .05,
**P< .01, ***P< .001; ****P< .0001, #P< .05, ##P< .01).
As we previously mentioned, sample processing and storage pro-
cedures are the main pre-analytic factors that may influence salivary
Lf concentration. Sample storage temperature and time after thaw-
ing may give different concentration values of salivary Lf. To analyze
possible variations over time on salivary protein concentration after
thawing, we analyzed salivary Lf concentration at different timepoints.
The samples were stored at –80◦C immediately after collection and
the analysis was carried out starting the day when the samples were
thawed (timepoint zero), and at 5, 10, and 15 days thereafter. The sta-
bility of 4◦C stored salivary samples was evaluated during these 15
days. At these timepoints, bench-top sample temperature was main-
tained at 4◦C. We found that the Lf concentration of salivary samples
was highest at baseline (–80◦C). Salivary Lf concentration remained
stable during the first 10 days and significantly decreased by day 15
after thawing (≈30%; Figure 1A). Samples that underwent no, or only
one freezing/thawing cycle, did not showdifferences in salivary protein
concentration (Figure 1B). After two freezing/thawing cycles, Lf con-
centration in saliva progressively decreased, with a significant reduc-
tion from the third cycle (Figure1C). Such concentration reductionmay
have been due to protein denaturalization.
We investigated the possible variability in salivary Lf concentration
linked to the circadian cycle. Saliva flow ratemayvarydependingon the
collection time during the day.We did not find statistical differences in
salivary Lf levels between collected samples from the same subject in
the morning and 8 hours later (Figure 1D). Our results are consistent
with previous findings in which either non-significant diurnal or day-
to-day variation on salivary Lf levels in samples obtained from 20- to
25-year-old male subjects were reported.16
It is known that age may influence salivary Lf production and this
maybe related to impaired innate-immunedefensesmaking theelderly
more susceptible to infections. Therefore, age-related differences in
salivary Lf levels were also analyzed. A gradual reduction in salivary
Lf concentration was observed in subjects from their fourth decade
onward (Figure 1E).
The effect of physical activity on salivary Lf levels was also analyzed.
We found that after 1 hour of moderate physical activity salivary Lf
levels significantly increased. Such increase was evaluated in 10 adult
participants compared to their levels analyzed just before the exercise
(Figure 1F).
Regarding the possible effects of AChE inhibitor treatment on sali-
vary protein production, no variations were found in total protein
content when this was analyzed in mild-to-moderate AD patients
recruited fromour recent study1 and grouped intomedicated and non-
medicated groups (Figure 1G). Specific analysis of salivary Lf levels
showed that they were significantly increased in AD patients under
AChE inhibitor treatment (Figure 1H). These results may suggest pos-
sible specific immunity deregulation in AD with effects on salivary Lf
release.17 Regarding the possible effects of memantine treatment on
salivary protein production, we mainly recruited patients with mild to
moderate AD and in fewer numbers, patientswith severe AD. As a con-
sequence only five AD patients were treated with memantine. We did
not find significant differences in total protein content or salivary Lf
levels in memantine-treated patients.
3 DETAILED METHODS AND RESULTS
The lack of standardized pre-analytical procedures in biomarkers
research may cause a huge variability in the results obtained. It
is important, therefore, to get a unified pre-analytical protocol
that will help to standardize the specific biomarker measurements
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F IGURE 1 Salivary lactoferrin (Lf) concentration changes. A, Relative Lf concentration in salivary samples collected from four subjects (mean
age 66.9 years) stored at 4◦C for 15 days. Samples were frozen at –80◦C after collection. Then, they were thawed andmaintained at 4◦C. Values
after thawing were compared to the baseline levels from samples stored at –80◦C stated as 100%. Data are expressed in percentage and are
shown asmean± standard error of themean (SEM). Differences between groups were assessed using one-way analysis of variance (ANOVA)
followed by the Bonferroni test. **P< .01 versus day 0; #P< .05 versus day 5. B, Effect of freezing/thawing on salivary Lf concentration. Salivary Lf
concentration in four subjects’ samples (mean age 66.9 years) that had not been subjected to any freeze/thaw cycle (point 0) compared to samples
from the same subjects that had been subjected to one freeze–thaw cycle (point 1). Connecting lines between point 0 and point 1 represent Lf
values from the same subject. Data show individual values of Lf concentration. C, Relative salivary Lf concentration in samples from eight subjects
(mean age 66.9 years) related to the number of freeze–thaw cycles. Salivary Lf levels after only one freeze–thaw cycle were used as the baseline
value and stated as 100%. Data are expressed in percentage and are shown asmean± SEM. Differences between groups were assessed using
one-way ANOVA followed by the Bonferroni test. **P< .01, ***P< .001, ****P< .0001 versus cycle 1; #P< .05, ##P< .01 versus cycle 2. D, Salivary
Lf levels in samples collected from 10 patients (mean age 52.5 years) at 10 am and after 8 hours (6 pm). Results showed no significant diurnal or
day-to-day variation of Lf concentration. Data are shown asmean± SEM. E, Salivary Lf levels from 20- to 80-year-old subjects (n= 12 to 37
subjects per group). Data are shown asmean± standard deviation (SD). Differences between groups were assessed using the Kruskal-Wallis test.
**P< .01 versus 30 y/o; ###P< .001; ####P< .0001 versus 40 y/o. F, Salivary Lf levels in samples collected from 10 subjects (mean age 52.5 years
old) before and after physical exercise performance (1 hour training). Saliva was collected at two timepoints: pre-exercise; and immediately after
exercise cessation. Data are shown asmean± SEM. Differences between groups were assessed using Student’s t-test. **P< .01. G, Total protein
concentration in saliva samples collected fromAlzheimer’s disease (AD) patients (mean age 67.2 years) with (n= 12) or without (n= 12)
acetylcholinesterase (AChE) inhibitor treatment. The results showed no significant variation in protein concentration. Data are shown asmean±
SEM. H, Salivary Lf levels fromAD patients (mean age 67.2 years) with (n= 42) or without (n= 27) AChE inhibitor treatment. Treated AD patients
showed higher salivary Lf levels. Data are shown asmean± SEM. Differences between groups were assessed using Student’s t-test.
*P< .05
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establishing global cut-offs.18 The present study aimed at checking
salivary Lf concentration–affecting factors. This will help to develop
unified protocols for pre-analytical handling of saliva samples obtain-
ing reliable measurements of Lf. Widespread implementation of AD
biomarkers in routine clinical practice requires the establishment of
standard operating procedures for such biological samples.
It is known sample protein concentration may be affected by sev-
eral factors including sample handling. Collection and storage condi-
tions must affect the levels of all proteins contained in the sample
equally. On the other hand, intrinsic and extrinsic factors affecting
donors might have influenced the production of specific proteins con-
tained in the sample. The diagnostic power of a new biomarker may
be determined by those factors that can modulate its expression. In
this study, we assessed whether salivary Lf concentration in samples
from AD patients and healthy donors is affected by the storage con-
ditions and the freezing/thawing cycles after collection. Additionally,
we have evaluated the impact of extrinsic factors affecting donors,
including circadian rhythm, exercise, age, andmedication on salivary Lf
production.
Although the biological sample transport between different labora-
tories could be easier at 4◦C, it may have detrimental consequences on
Lf-related results. A slight but non-significant reduction in Lf concen-
tration was observed in aliquots thawed once and maintained at 4◦C
for 10 days, compared to a reference sample (aliquot maintained at –
80◦C, not thawed until analysis). In any case, our findings indicate that
Lf concentration remainedunaltered in saliva samples storedat4◦Cfor
at least 10 days, but we recommend avoiding 4◦C storage above that
time.
Freezing and thawing procedures may introduce concentration gra-
dients in biological samples. To avoid such gradients, thorough mix-
ing of the tube contents is necessary. In this regard, several works
investigated the biophysical properties of sample-containing proteins
or proteins themselves.19–20 In these studies it was demonstrated
that repeated freeze–thaw cycles may affect protein stability and con-
centration. Authors indicate that using cryoprotectants in the sample
buffer would be beneficial but such effect would disappear after four
to five freeze–thaw cycles.19–20
The reported reduction of salivary Lf concentration after repeated
freeze–thaw cycles highlights the importance of avoiding such
freezing–thawing. This would minimize sample degradation that might
givemisleading Lf concentration values.
Other possible influences, including lifestyle and exposure to envi-
ronmental factors, may affect salivary Lf production. Several studies
showed that salivary Lf concentration might be affected by circadian
rhythms and physical activity14,21–22 or environmental and lifestyle
factors, including habits like smoking and medication intake.23–25 Our
results show no between-day related differences on salivary Lf con-
centration. Although many studies show that protein release and
metabolic pathways may respond instantaneously to changes in cir-
cadian clocks, our findings are consistent with other studies in which
researchers did not find significant between-daydifferences in concen-
tration of Lf in saliva16 and tears.26
Herewe show that salivary Lf concentration reduceswith age, being
significant in the fourth decade. Various researchers observed reduced
Lf and peroxidase activity in healthy elderly subjects, thus represent-
ing a challenge for oral tissues due to imbalances in salivary antimi-
crobial agents.27–29 Histological studies carried out on salivary glands
have shown that the proportional volume of acinar cell secretion was
reducedwith age.30 Thiswas considered one of themajor causes of dry
mouth.31 Acinar cells in the salivary glands secrete Lf. Thus, histological
changes affecting the salivary glandmay result in overall salivary gland
hypofunction and reduced Lf levels.
Wealso found thatphysically active compared to sedentary subjects
might benefit from increased immunological protectionmechanisms at
different levels. Several studies reported that salivary levels of antibac-
terial proteins/immunological agents were higher after exercise in
physically active people compared to those observed in sedentary
subjects. These observations highlight that regular exercise/training
improves immune/inflammatory status.14,32–34 Because physical activ-
ity and exercise result in increased salivary Lf levels, we propose that
physically active people may have greater protection against infec-
tions by exercise-modulated changes to the immune/inflammatory
response. This observation reinforces the hypothesis that physical
activity intervention could be a low-cost and low-risk protective factor
for AD36 and thus, we encourage regular physical activity intervention
for patients with AD.
The impact of currently used AD treatments on salivary Lf con-
centration must be also explored. We estimated total protein con-
tent in collected saliva samples from AD patients, recruited from our
recent study.1 Subjects were grouped as patients under treatment or
not under treatment with AChE inhibitors, and patients under treat-
ment with or not under treatment with memantine, which are drugs
currently used for AD treatment. Although the secretion of salivary
proteins is mediated by acetylcholine release under autonomic ner-
vous system control,15 no changes were found in total protein con-
centration in saliva samples collected from AD patients, with or with-
out AChE inhibitor treatment. However, salivary Lf levels were sig-
nificantly increased in AD patients under AChE inhibitors treatment
suggesting a protein-specific effect. This could be explained as treat-
ment with AChE inhibitors increases acetylcholine levels, thus upregu-
lating Lf release in salivary glands. Such upregulation was reported in a
study in which it was demonstrated that vasoactive intestinal peptide,
which is released along with acetylcholine by parasympathetic nerves,
stimulates Lf release in submucosal glands.35 Stimulation of parasym-
pathetic neurons leads to the release of acetylcholine, which acts
upon muscarinic receptors on salivary glands.15 AChE catalyzes the
breakdown of acetylcholine, thus enzyme inactivation leads to acetyl-
choline accumulation, resulting in augmented muscarinic receptor-
mediated stimulation of Lf secretion. Regarding memantine, we did
not find differences in salivary Lf concentration between samples
from memantine-treated compared to samples from non-memantine–
treated patients.
All of these differences are important factors to be considered and
investigated in future multicenter studies. Our present results pro-
vide interesting and convincing evidence showing salivary Lf variability
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depends on extrinsic factors. Also, our work further supports the idea
that salivary Lf be considered a sensitive and non-invasive biomarker
for AD.
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